Sotrovimab no longer authorized to treat COVID-19 in areas with high BA.2 frequency

The monoclonal antibody sotrovimab is no longer authorized by the FDA to treat COVID-19 in certain U.S. regions with high frequency of the omicron BA.2 subvariant.
In a statement released March 25, the FDA said it was limiting the use of sotrovimab (Xevudy, GlaxoSmithKline) in some U.S. regions, mostly along the east coast, following data showing that the authorized dose of the monoclonal antibody — 500 mg — is unlikely to be effective against the BA.2 subvariant.
Regions where sotrovimab is no longer authorized for COVID-19 treatment, until further notice, are:
Based CDC Nowcast

The monoclonal antibody sotrovimab is no longer authorized by the FDA to treat COVID-19 in certain U.S. regions with high frequency of the omicron BA.2 subvariant.
In a statement released March 25, the FDA said it was limiting the use of sotrovimab (Xevudy, GlaxoSmithKline) in some U.S. regions, mostly along the east coast, following data showing that the authorized dose of the monoclonal antibody — 500 mg — is unlikely to be effective against the BA.2 subvariant.
Regions where sotrovimab is no longer authorized for COVID-19 treatment, until further notice, are:
Based CDC Nowcast